LYONS GARY A 4
4 · NEUROCRINE BIOSCIENCES INC · Filed Aug 15, 2024
Insider Transaction Report
Form 4
LYONS GARY A
Director
Transactions
- Sale
Common Stock
2024-08-13$150.43/sh−11,570$1,740,450→ 119,047 total - Exercise/Conversion
Common Stock
2024-08-13$42.76/sh+11,570$494,733→ 130,617 total - Exercise/Conversion
Non-Qualified Stock Option
2024-08-13−11,570→ 0 totalExercise: $42.76Exp: 2025-05-28→ Common Stock (11,570 underlying)
Footnotes (4)
- [F1]113,064 of the reported shares are held by the Gary A. Lyons Revocable Living Trust U/A 6/8/12, of which the Reporting Person has voting and investment power.
- [F2]The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2024
- [F3]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $150.00 to $151.30. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range
- [F4]The option was granted May 28, 2015 and vested in 12 equal monthly installments beginning June 28, 2015. These options will expire ten years from the date of grant on May 28, 2025.